Advertisement
Screener

ORIC PHARMACEUTICALS, INC. (ORIC) Executive Pay versus Performance: Pay versus Performance

ORIC PHARMACEUTICALS, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: PEO Jacob M. Chacko, M.D.; PEO total compensation $5.57M; PEO compensation actually paid $5.69M; Other NEO average total compensation $2.26M.
  • 2024-12-31: PEO total compensation $5.28M; PEO compensation actually paid $4.27M; Other NEO average total compensation $2.21M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-31Jacob M. Chacko, M.D.$5.57M$5.69M$2.26M$2.30M$88.91-$129.47M2026-04-28
2024-12-31$5.28M$4.27M$2.21M$1.85M$87.72-$127.85M2026-04-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
OMEROS CORP (OMER)United States$1.456B5.50
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
Avalyn Pharma Inc. (AVLN)United States$1.267B
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62